# Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes

> **NCT00715663** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1584 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Delivery Systems

## Interventions

- **DRUG:** biphasic insulin aspart 30

## Key facts

- **NCT ID:** NCT00715663
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 1584 (ACTUAL)
- **Last updated:** 2016-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00715663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00715663, "Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00715663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*